A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy
Lynn R Webster,1 Martin E Hale,2 Tadaaki Yamada,3 James E Wild4 1PRA Health Sciences, Salt Lake City, UT, USA; 2Gold Coast Research LLC, Plantation, FL, USA; 3Shionogi, Inc., Florham Park, NJ, USA; 4Upstate Clinical Research Associates, Williamsville, NY, USACorrespondence: Lynn R WebsterPRA Health...
Main Authors: | Webster LR, Hale ME, Yamada T, Wild JE |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-03-01
|
Series: | Journal of Pain Research |
Subjects: | |
Online Access: | https://www.dovepress.com/a-renal-impairment-subgroup-analysis-of-the-safety-and-efficacy-of-nal-peer-reviewed-article-JPR |
Similar Items
-
Spotlight on naldemedine in the treatment of opioid-induced constipation in adult patients with chronic noncancer pain: design, development, and place in therapy
by: Stern EK, et al.
Published: (2018-01-01) -
Effectiveness of Naldemedine Compared with Magnesium Oxide in Preventing Opioid-Induced Constipation: A Randomized Controlled Trial
by: Fuyuki, A., et al.
Published: (2022) -
Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies
by: Saito Y, et al.
Published: (2018-12-01) -
Prevention and management of diarrhea associated with naldemedine among patients receiving opioids: a retrospective cohort study
by: Yusuke Takagi, et al.
Published: (2020-01-01) -
Opioid therapy duration before naldemedine treatment is a significant independent risk of diarrhea: a retrospective cohort study
by: Akiharu Okamoto, et al.
Published: (2021-02-01)